Combination chemotherapy

• US 20030176403A1
• Filed: 03/17/2003
• Published: 09/18/2003
• Est. Priority Date: 08/29/1997
• Status: Abandoned Application

• Current Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Original Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Inventors: Trump, Donald J., Johnson, Candace S.
• Application Number:
  US10/390,234
• Publication Number:
  US 20030176403A1
• Time in Patent Office: Days
• US Class Current: 514/168
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/335 having oxygen as the only ring hetero atom, e.g. fungichromin
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/55 having seven-membered rings, e.g. azelastine, pentylenetetrazole
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a method of treating a patient with vitamin-D or a derivative thereof involving the adjunctive administration of zoledronate.

Claims

1. In an improved method for treating a patient by administering vitamin D or a derivaitive thereof to the patients the improvement comprising adjunctively administering zolecdroniate to the patient.

2. The method of claim 1, wherein the zoledronate is administered prior to administration of the vitamin D or derivative.

3. The method of claim 1, wherein the zoledronate is administered at a dosage between about 5 μ

m/kg body weight of the patient and about 25 μ

g/kg body weight of the patient.

4. The method of claim 1, wherein the vitamin D derivative is a nonhypercalcemic analog.

5. The method of claim 1, wherein the vitamin D derivative is 1,25D₃.